On March 14, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, reported that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held in Orlando, Fla., April 14-19, 2023 (Press release, Harpoon Therapeutics, MAR 14, 2023, View Source [SID1234628703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth of data from Harpoon’s five poster presentations at AACR (Free AACR Whitepaper) supports further investigation of additional tumor targets, combination approaches with TriTACs, as well as our next-generation technology platform with conditionally active T cell engager prodrugs, or ProTriTACs," said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics. "Additionally, the preclinical data investigating the activity of TriTAC in an immunocompetent mouse model provide further validation of our ongoing and planned clinical efforts with HPN328 and HPN217, leveraging our proprietary TriTAC T cell engager platform. We look forward to further validation in the clinic as our research efforts continue."

Details of the AACR (Free AACR Whitepaper) poster presentations are as follows:

Title: Long-term anti-tumor immunity induced by HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, in a preclinical immunocompetent mouse model
Abstract Number: 4131
Session: Immunology/Determinants of Immunotherapeutic Effectiveness
Session Date, Time: Tuesday, April 18, 9 a.m. – 12:30 p.m. ET
Location: Poster Section 24

Title: Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model
Abstract Number: 5070
Session: Immunology/Combination Immunotherapies 1
Session Date, Time: Tuesday April 18, 1:30 – 5 p.m. ET
Location: Poster Section 21

Title: Anti-tumor activity of HPN217, a BCMA-targeting tri-specific T cell engager, is enhanced by γ-secretase inhibitors in preclinical models
Abstract Number: 5081
Session: Immunology/Combination Immunotherapies 1
Session Date, Time: Tuesday April 18, 1:30 – 5 p.m. ET
Location: Poster Section 21

Title: TROP2 ProTriTAC, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors
Abstract Number: 2928
Session: Immunology/Therapeutic Antibodies 2
Session Date, Time: Monday April 17, 1:30 – 5 p.m. ET
Location: Poster Section 23

Title: ITGB6 ProTriTAC, a protease-activated T cell engager prodrug targeting Integrin-β6 for the treatment of solid tumors
Abstract Number: 2927
Session: Immunology/Therapeutic Antibodies 2
Session Date, Time: Monday April 17, 1:30 – 5 p.m. ET
Location: Poster Section 23

The posters will also be available on Harpoon’s website following the presentations.

For more details about the AACR (Free AACR Whitepaper) Annual Meeting, please visit:
View Source